youtube_live
Q1 2026 tulu • välja lastud • Aktsiakasum ületati +10 388,80% • Tulu ületati +0,22%
Vaadake tulemusichevron_right
GSK:NYSE
GSK plc
52,31 $
0,00%
(0,00) 1 p
51,92 $
arrow_downward
−0,75% (−0,39)todayEnne avanemist
Suletud: 30. apr, 16:00:03 GMT −4 · USD
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GSK põhistatistika genereerimine…
Ava
51,91 $
Kõrge
52,63 $
Madal
51,63 $
Turu kapit.
106,98 mld
Keskm. maht
4,24 mln
Maht
3,14 tuh
Dividend
3,39%
Kvartaalne dividend
0,44 $
Dividendikuupäev
14. mai 2026
Hinna ja tulu suhe
13,63
52 näd kõrgeim
61,70 $
52 näd madalaim
35,45 $
Aktsiatulu
3,84 $
Beeta
0,37
Käibivad aktsiad
2,03 mld
Töötajate arv
67 tuh
Uudised
Erinevatest veebiallikatest
Morningstar Canada
·
17 tunni eest
GSK Earnings: Strong Start to the Year Due to Specialty Medicines and Shingrix
Proactive financial news
·
18 tunni eest
JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited
Traders Union
·
1 päeva eest
GSK stock moves sideways after net debt rise from investments and buybacks
GSK
·
1 päeva eest
GSK delivers strong Q1 performance and start to 2026
Profiil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Teave üksuse GSK plc kohta
TegevjuhtEmma Walmsley | Emma Walmsley
Töötajad66,8 tuh
Asutatud27. dets 2000
Peakontorid-
Sektor-
Veebisaitgsk.com
AI genereeritud sisu võib sisaldada vigu. Lisateave